Stocks · News reference
Filed: 2026-08-04 AccNo: 0001570562-26-000083 Size: 203 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix" or the "Company") today announces that David Gill has been appointed Chair of the Board, effective immediately.Mr. Gill joined Telix as a
HC Wainwright & Co. analyst Douglas Tsao reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $13 price target.
Evolus (NASDAQ:EOLS) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.13) by 0 percent. This is a 47.83 percent increase over losses of $(0.23) per share from the same
Evolus (NASDAQ:EOLS) raises FY2026 sales outlook from $327.000 million-$337.000 million to $330.000 million-$337.000 million vs $330.445 million estimate.